Recombinant Human Bone Morphogenetic Protein Receptor, Type IA, GST-tagged

• Cat.No.: BMPR1A-991H
• Product Overview: Recombinant human BMPR1A (187-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Specification

• Cat. No.: BMPR1A-991H
• Description: BMPR1A (also known as bone morphogenetic protein receptor 1A) is a member of the transmembrane serine/threonine kinase family that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. BMPR1A act as a minor susceptibility gene for PTEN-mutation-negative Cowden syndrome. BMPR1A regulates the PTEN protein levels by decreasing PTEN"s association with the degradative pathway. BMPR1A trafficking plays a significant role in FOP pathogenesis and is also involved in human T-cell differentiation.
• Applications: Kinase Assay; Western Blot
• Molecular Weight: 66 kDa
• Expression System: Sf9 insect cells using baculovirus
• Species: Human
• Form: Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25 % glycerol.
• Specific Activity: 1.2 nmol/min/mg
• Purity: > 90 %
• Concentration: 0.1 ug/ul
• Sequences: 187-end
• Storage: Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
• Pathways: Cytokine-cytokine receptor interaction; TGF-beta signaling pathway; Signaling by BMP; Endochondral Ossification; Heart Development

Gene Information

• Gene Name: BMPR1A bone morphogenetic protein receptor, type IA [ Homo sapiens ]
• Official Symbol: BMPR1A
• Synonyms: BMPR1A; bone morphogenetic protein receptor, type IA; ALK3; SKR5; CD292; ACVRLK3; 10q23del; bone morphogenetic protein receptor type-1A; ALK-3; BMPR-1A; BMP type-1A receptor; activin receptor-like kinase 3; activin A receptor, type II-like kinase 3; serine/threonine-protein kinase receptor R5; Bone morphogenetic protein receptor type-1A; BMPR-1A; Activin receptor-like kinase 3; Serine/threonine-protein kinase receptor R5; EC 2.7.11.30; OTTHUMP00000020014
• Gene ID: 657
• mRNA Refseq: NM_004329
• Protein Refseq: NP_004320
• MIM: 601299
• UniProt ID: P36894
• Chromosome Location: 10q22.3
• Function: ATP binding; SMAD binding; magnesium ion binding; activin receptor activity, type II; metal ion binding; nucleotide binding; protein binding; protein homodimerization activity; protein serine/threonine kinase activity; receptor activity; transferase activity; transforming growth factor beta receptor activity; transmembrane receptor protein serine/threonine kinase activity

Reviews

11/06/2021

The enzyme activity of this protein reached the expected level and was able to play a role in the specific reaction.

10/20/2021

When experimenting with this protein, stable and repeatable results can be obtained.

03/08/2021

This product has strict quality control and complies with relevant industry standards.

Q&As

What disease might abnormal BMPR1A levels suggest?

Abnormal levels of BMPR1A may suggest skeletal dysplasia, tumors, etc., but its specificity and sensitivity need to be further studied.

Is there a mutation type of BMPR1A?

The types of mutations in BMPR1A include point mutations, insertions/deletions, duplications, etc., which may cause structural and functional abnormalities of the protein.

How are mutations in BMPR1A detected and analyzed?

Mutations in BMPR1A can be detected and analyzed by methods such as whole-genome sequencing or target region sequencing to understand the impact of mutations on protein structure and function.

How to study the regulatory mechanism of BMPR1A?

Studying the regulatory mechanism of BMPR1A requires a comprehensive use of various experimental methods and techniques, such as gene knockout, transcriptome analysis, and protein-protein interactions.

What are the applications of BMPR1A in medical treatment?

BMPR1A can be used as a biomarker in medical treatment to help monitor disease progression and treatment efficacy. In addition, therapeutics targeting BMPR1A, such as gene therapy or modulating its expression, are also being studied.

What diseases can BMPR1A deficiency or aberrant expression cause?

Deficiency or abnormal expression of BMPR1A may be related to some skeletal dysplasia diseases, tumors, etc.